Teleflex (NYSE:TFX) Stock Rating Lowered by Zacks Research

Teleflex (NYSE:TFX) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Monday,Zacks.com reports.

Several other research firms have also commented on TFX. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a research report on Monday, December 29th. Needham & Company LLC upped their target price on shares of Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Wall Street Zen cut Teleflex from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Truist Financial boosted their price objective on Teleflex from $120.00 to $135.00 and gave the stock a “hold” rating in a research report on Thursday, December 18th. Finally, Royal Bank Of Canada raised their target price on Teleflex from $115.00 to $125.00 and gave the company a “sector perform” rating in a research report on Friday, February 27th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $140.83.

Teleflex Price Performance

TFX opened at $122.02 on Monday. The company has a market capitalization of $5.39 billion, a P/E ratio of -5.94, a PEG ratio of 0.76 and a beta of 0.87. The company has a 50-day moving average of $111.31 and a 200-day moving average of $118.70. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.01 and a current ratio of 2.54. Teleflex has a 1-year low of $100.18 and a 1-year high of $143.32.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, February 26th. The medical technology company reported $1.93 earnings per share for the quarter, missing the consensus estimate of $3.73 by ($1.80). The firm had revenue of $569.00 million during the quarter, compared to the consensus estimate of $912.57 million. Teleflex had a negative net margin of 30.56% and a positive return on equity of 14.30%. The firm’s quarterly revenue was down 28.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.89 earnings per share. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Equities analysts expect that Teleflex will post 13.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Teleflex

A number of institutional investors have recently bought and sold shares of the stock. Josh Arnold Investment Consultant LLC acquired a new stake in shares of Teleflex during the fourth quarter valued at approximately $32,341,000. Invesco Ltd. grew its stake in Teleflex by 3.0% in the fourth quarter. Invesco Ltd. now owns 162,882 shares of the medical technology company’s stock valued at $19,878,000 after purchasing an additional 4,807 shares in the last quarter. Alberta Investment Management Corp purchased a new stake in shares of Teleflex during the 4th quarter worth about $1,318,000. Vident Advisory LLC lifted its holdings in shares of Teleflex by 2.8% during the 4th quarter. Vident Advisory LLC now owns 6,992 shares of the medical technology company’s stock valued at $853,000 after buying an additional 188 shares during the last quarter. Finally, State of Tennessee Department of Treasury grew its stake in shares of Teleflex by 4.7% in the 4th quarter. State of Tennessee Department of Treasury now owns 22,374 shares of the medical technology company’s stock valued at $2,731,000 after buying an additional 998 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.